Replies to post #519892 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

MHRA already endorsed the trial design

They endorsed using predefined ECAs in a P2.

That is a far cry from switching to ECAs in a P3 after the randomized comps (including OS) failed.